Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Surgery
Cell adhesion
Bacteria
Microbiote
Anti-TNF
Clinical trial
COLON-CANCER
Epigénétiques
Clinical guidelines
RISK
Inflammatory bowel diseases
Patients experience
Vedolizumab
Screening
Gene methylation
Eradication
Cost effectiveness
Anti-TNF agents
Maintenance therapy
Genes
Colonic epithelial primary cells
Inclusion
DNA METHYLATION
Tailored therapy
DNA methylation
MALT
T1118 translocation
Tuberculosis
Helicobacter pylori
Inhibitor
Colon cancer
Cancer
Intestinal crypts
Colorectal cancer
Safety
Immune cells
Crohn’s disease
Contraindication
Heart disease risk factors
Bactéries
IL12
Monitoring
Immunosuppressant
IBD
Fecal microbiota
HIV
Primary sclerosing cholangitis
Survival
Therapeutics
MORTALITY
Ulcerative colitis
Ustekinumab
Venous thromboembolism
18 FDG-PET/CT
Disease Progression
Dysbiose
CARCINOGENESIS
Acceptability
Crohn's disease
Disease progression
PCR
Methylation
Rituximab
MARKER
Small molecules
Colectomy
Over 80s
Epigenetics
Résistance
Eligibility
Neoadjuvant chemotherapy
Microbiota
Alkylating agents
Patient-reported outcome
Gene expression
Effectiveness
Endoscopic treatment
MICROBIOTA
Parvimonas micra
Rituximab plus chlorambucil
Kidney diseases
Upper gastrointestinal tract
Dysbiosis
Biomarker
Original Article Clinical
Drug
Consensus
Colon
Biologics
Colorectal cancer Colibactin and lipids
Thérapie ciblée
Resistance
IL23
Algorithm
Inflammatory bowel disease
Stricture
Gènes
Inflammatory Bowel Diseases
Disability
Méthylation
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|